Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Should a Bulky Mediastinal Mass ≥7cm in the Longest Dimension be Considered an Adverse Prognostic Factor in Patients with Advanced Hodgkin Lymphoma and Negative Interim PET/CT?

Eldad J Dann, MD, Rebeca Lopez-Alonso, Shunan Qi, Tania Mashiach, Michal Weiler-Sagie, Joachim Yahalom, MD

Blood (2019) 134 (Supplement_1): 4051.

https://doi.org/10.1182/blood-2019-122824

Published: 2019

Journal Articles

Reduction of Vertebral Bone Density in Patients with Hodgkin Lymphoma Above 30 Years of Age Correlates with the Cumulative Dose of Steroids They Receive As Part of Treatment Protocol

Nadav Ofshenko, Eyal Bercovich, Tania Mashiach, Michal Weiler-Sagie, Daniela Militianu, Eldad J Dann, MD

Blood (2019) 134 (Supplement_1): 4042.

https://doi.org/10.1182/blood-2019-122675

Published: 2019

Journal Articles

Preoperative Anemia and Blood Transfusion Requirement during Hip Surgery: Synthetic and Real Patient Cohort Data

Tsofia Inbar, MD, Eldad J Dann, MD

Blood (2019) 134 (Supplement_1): 3693.

https://doi.org/10.1182/blood-2019-125252

Published: 2019

Journal Articles

A Simple Model for Predicting Post-Autologous Stem Cell Transplantation Outcome in Patients with Relapsed/Primary Refractory Hodgkin Lymphoma

Eldad J Dann, MD, Shani Sobol, Tania Mashiach, Tamar Katz, PhD, Tsila Zuckerman, MD

Blood (2018) 132 (Supplement 1): 2150.

https://doi.org/10.1182/blood-2018-99-110713

Published: 2018

Journal Articles

Cognitive Impairment in Hodgkin Lymphoma Survivors

Estherina Trachtenbrg, MSc, BA, Tania Mashiach, Tamar Tadmor, MD, Judith Aharon-Peretz, MD, Eldad J Dann, MD

Blood (2017) 130 (Supplement 1): 3450.

https://doi.org/10.1182/blood.V130.Suppl_1.3450.3450

Published: 2017

Journal Articles

Real-Life Experience of Nivolumab in Heavily Pretreated Relapsed and Refractory Classical Hodgkin Lymphoma

Ohad Benjamini, MD, David Lavie, MD, Eldad J Dann, MD, Chava Perry, MDPhD, Ory Rouvio, MD, Olga Shvetz, MD, Anatoly Nemets, MD, Ruth Perets, MD PhD, Revital Saban, MD, Avichai Shimoni, MD, Dina Ben-Yehuda, MD, Arnon Nagler, Abraham Avigdor, MD

Blood (2016) 128 (22): 3008.

https://doi.org/10.1182/blood.V128.22.3008.3008

Published: 2016

Journal Articles

Can We Improve the Predictive Value of Interim PET/CT Using a New Prognostic Model for Advanced Hodgkin Lymphoma?

Eldad J. Dann, MD, Osnat Bairey, MD, Rachel Bar-Shalom, MD, Tanya Mashiach, MSc, Elinor Barzilai, BSc, Abraham Korenberg, MD, Luiza Akria, MD, Tamar Tadmor, MD, Kalman Filanovsky, MD, Uri Abadi, MD, Olga Kagna, MD, Rosa Ruchlemer, MD, Neta Goldschmidt, MD, Netanel A. Horowitz, MD, David Lavie, MD, Dina Ben-Yehuda, MD, Ofer Shpilberg, MD, Ora B. Paltiel, MDM, MSc

Blood (2016) 128 (22): 3001.

https://doi.org/10.1182/blood.V128.22.3001.3001

Published: 2016

Journal Articles

Addition of Intermediate-Dose Methotrexate Is Beneficial in Terms of Both Progression-Free Survival and Overall Survival for Patients with Diffuse Large B Cell Lymphoma Receiving Either R-CHOP or CHOP

Eldad J. Dann, MD, Neta Goldschmidt, MD, Vered Heffes, MD, Tanya Mashiach, MSc, Moshe E. Gatt, MD, Netanel A Horowitz, MD

Blood (2016) 128 (22): 1877.

https://doi.org/10.1182/blood.V128.22.1877.1877

Published: 2016

Journal Articles

Intermediate Dose Methotrexate Improves Overall Survival and Progression-Free Survival of Patients with Diffuse Large B Cell Lymphoma Treated with the R-CHOP or CHOP Regimen

Eldad J Dann, MD, Vered Heffes, BsC, Tatiana Mashiach, MSc, Noam Benyamini, MD, Irit Avivi, MD, Netanel A Horowitz, MD

Blood (2015) 126 (23): 2698.

https://doi.org/10.1182/blood.V126.23.2698.2698

Published: 2015

Journal Articles

Relapse Mechanism of FLT3-ITD Positive AML and Cell Differentiation Blockage

Michal Hayun, PhD, Maria Zaatra, Chen Itzkovitch, Dvora Sahar, PhD, Eldad J. Dann, MD, Igal Louria-Hayon, PhD, Yishai Ofran, MD

Blood (2015) 126 (23): 4961.

https://doi.org/10.1182/blood.V126.23.4961.4961

Published: 2015

Journal Articles

Tailored Therapy in Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT: Israeli H2 Study

Eldad J Dann, MD, Osnat Bairey, MD, Rachel Bar-Shalom, MD, Elinor Sabbag, BSc., Marina Izak, MD, Abraham Korenberg, MD, Luiza Akria, MD, Dina Attias, MD, Kalman Filanovsky, MD, Uri Abadi, MD, Rosa Ruchlemer, MD, Roxolyana Abdah-Bortnyak, MD, Neta Goldschmidt, MD, Ron Epelbaum, MD, Netanel Horowitz, David Lavie, MD, Dina Ben Yehuda, MD, Ofer Shpilberg, MD, Ora B. Paltiel, MDM, MSc

Blood (2014) 124 (21): 4409.

https://doi.org/10.1182/blood.V124.21.4409.4409

Published: 2014

Journal Articles

Primary Splenic Diffuse Large B-Cell Lymphoma (PS-DLBCL): Splenectomy Improves Survival

Osnat Bairey, MD, Lev Shvidel, MD, Chava Perry, MD PhD, Eldad J Dann, MD, Rosa Ruchlemer, MD, Tamar Tadmor, MD, Neta Goldschmidt, MD

Blood (2014) 124 (21): 4439.

https://doi.org/10.1182/blood.V124.21.4439.4439

Published: 2014

Journal Articles

High Risk Advanced Stage Hodgkin Lymphoma Is Well Controlled with 2 Cycles of Escalated Beacopp Followed By 4 Cycles of ABVD in Patients Who Rapidly Achieve Metabolic CR on Interim PET/CT Scan

Meirav Kedmi, MD, Arie Apel, MD, Tima Davidson, MD, Elinor Goshen, MD, Yaron Davidovitz, MD, Miriam Berkowicz, MD, Itai Levi, MD, Eldad J. Dann, MD, Aaron Polliack, MD, Arnon Nagler, MD, Abraham Avigdor, MD

Blood (2014) 124 (21): 4442.

https://doi.org/10.1182/blood.V124.21.4442.4442

Published: 2014

Journal Articles

Hodgkin Lymphoma In First Remission: Routine PET/CT Imaging Is Not Superior To Clinical Follow-Up For Patients Without Residual Mass: Results Of a Bi-National Study Including 368 Patients

Eldad J Dann, MD, Leanne Berkahn, MB ChB, FRACP, FRCPA, Tatiana Mashiach, MSc, Michael Frumer, Ariel Agur, Bridgett McDiarmid, MD, Rachel Bar-Shalom, MD, Ora B. Paltiel, MSc, FRCPC, Neta Goldschmidt, MD

Blood (2013) 122 (21): 2995.

https://doi.org/10.1182/blood.V122.21.2995.2995

Published: 2013

Journal Articles

Integration Of CT-Based Measurements Into PET Assessment Significantly Improves The Positive Predictive Value Of Surveillance FDG PET/CT In Patients With Diffuse Large B Cell Lymphoma

Noa Lavi, MD, Gali Shapira, MD, Ariel Zilberlicht, MD, Noam Benyamini, MD, Dan Farbstein, MD, Eldad J Dann, MD, Rachel Bar-Shalom, MD, Irit Avivi, MD

Blood (2013) 122 (21): 4296.

https://doi.org/10.1182/blood.V122.21.4296.4296

Published: 2013

Journal Articles

High-Dose Cyclophosphamide In Combination With G-CSF Versus G-CSF Alone For Mobilization Of Hematopoietic Stem Cells After Induction Therapy Including Velcade, Cyclophosphamide and Dexacort

Noam Benyamini, MD, Irit Avivi, MD, Eldad J Dann, MD, Tsila Zuckerman, MD, Lavi Noa, MD, Tami Katz, Ph.D

Blood (2013) 122 (21): 5369.

https://doi.org/10.1182/blood.V122.21.5369.5369

Published: 2013

Journal Articles

Six Cycles of BEACOPP Tailored Based on Interim Scintigraphy Provide Favorable Outcome for Patients with Standard and Advanced Risk Hodgkin Lymphoma and Female Fertility Is Preserved: Results of a 10-Year Follow-up

Eldad J Dann, MD, Zeev Blumenfeld, MD, Rachel Bar-Shalom, MD, Irit Avivi, MD, Menachem Ben-Shachar, MD, Odelia Goor, MD, Diana Libster, MD, Diana Gaitini, MD, Jacob M. Rowe, MD, Ron Epelbaum, MD

Blood (2011) 118 (21): 1564.

https://doi.org/10.1182/blood.V118.21.1564.1564

Published: 2011

Journal Articles

Reduced Specificity and Positive Predictive Value of Surveillance FDG-PET/CT for Diffuse Large Cell B Cell Lymphoma in the Rituximab Era

Irit Avivi, MD, Ariel Zilberlicht, MD, Eldad J Dann, MD, Jacob M. Rowe, MD, Ronit Leiba, MSc., Tal Faibish, MSc, Rachel Bar-Shalom, MD

Blood (2011) 118 (21): 1576.

https://doi.org/10.1182/blood.V118.21.1576.1576

Published: 2011

Journal Articles

Tailored Therapy In Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT, Can Lead to Modification and Safe Reduction In Therapy: Results of 134 Patients on the Israel National Hodgkin Study.

Eldad J. Dann, MD, Osnat Bairey, MD, Rachel Bar-Shalom, MD, Marina Izak, MD, Abraham Korenberg, MD, Luiza Akria, MD, Dina Attias, MD, Kalman Filanovsky, MD, Liana Abdach, MD, Neta Goldschmidt, MD, Ron Epelbaum, MD, Jacob M. Rowe, MD, Dina Ben Yehuda, MD, Ofer Shpilberg, MD, Ora B. Paltiel, MSc, FRCPC

Blood (2010) 116 (21): 2809.

https://doi.org/10.1182/blood.V116.21.2809.2809

Published: 2010

Journal Articles

Not All Positive Interim PET/CT Scans Are Reliably Predictive for Progression Free Survival in Hodgkin Lymphoma (HL) Patients. A Proposed Model for a Functional Scoring Scale.

Eldad J. Dann, MD, Ada Tamir, PhD, Ron Epelbaum, MD, Irit Avivi, MD, Menachem Ben-Shachar, MD, Diana Gaitini, MD, Jacob M. Rowe, MD, Rachel Bar-Shalom, MD

Blood (2008) 112 (11): 1452.

https://doi.org/10.1182/blood.V112.11.1452.1452

Published: 2008

NARROW

Should a Bulky Mediastinal Mass ≥7cm in the Longest Dimension be Considered an Adverse Prognostic Factor in Patients with Advanced Hodgkin Lymphoma and Negative Interim PET/CT?

Reduction of Vertebral Bone Density in Patients with Hodgkin Lymphoma Above 30 Years of Age Correlates with the Cumulative Dose of Steroids They Receive As Part of Treatment Protocol

Preoperative Anemia and Blood Transfusion Requirement during Hip Surgery: Synthetic and Real Patient Cohort Data

A Simple Model for Predicting Post-Autologous Stem Cell Transplantation Outcome in Patients with Relapsed/Primary Refractory Hodgkin Lymphoma

Cognitive Impairment in Hodgkin Lymphoma Survivors

Real-Life Experience of Nivolumab in Heavily Pretreated Relapsed and Refractory Classical Hodgkin Lymphoma

Can We Improve the Predictive Value of Interim PET/CT Using a New Prognostic Model for Advanced Hodgkin Lymphoma?

Addition of Intermediate-Dose Methotrexate Is Beneficial in Terms of Both Progression-Free Survival and Overall Survival for Patients with Diffuse Large B Cell Lymphoma Receiving Either R-CHOP or CHOP

Intermediate Dose Methotrexate Improves Overall Survival and Progression-Free Survival of Patients with Diffuse Large B Cell Lymphoma Treated with the R-CHOP or CHOP Regimen

Relapse Mechanism of FLT3-ITD Positive AML and Cell Differentiation Blockage

Tailored Therapy in Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT: Israeli H2 Study

Primary Splenic Diffuse Large B-Cell Lymphoma (PS-DLBCL): Splenectomy Improves Survival

High Risk Advanced Stage Hodgkin Lymphoma Is Well Controlled with 2 Cycles of Escalated Beacopp Followed By 4 Cycles of ABVD in Patients Who Rapidly Achieve Metabolic CR on Interim PET/CT Scan

Hodgkin Lymphoma In First Remission: Routine PET/CT Imaging Is Not Superior To Clinical Follow-Up For Patients Without Residual Mass: Results Of a Bi-National Study Including 368 Patients

Integration Of CT-Based Measurements Into PET Assessment Significantly Improves The Positive Predictive Value Of Surveillance FDG PET/CT In Patients With Diffuse Large B Cell Lymphoma

High-Dose Cyclophosphamide In Combination With G-CSF Versus G-CSF Alone For Mobilization Of Hematopoietic Stem Cells After Induction Therapy Including Velcade, Cyclophosphamide and Dexacort

Six Cycles of BEACOPP Tailored Based on Interim Scintigraphy Provide Favorable Outcome for Patients with Standard and Advanced Risk Hodgkin Lymphoma and Female Fertility Is Preserved: Results of a 10-Year Follow-up

Reduced Specificity and Positive Predictive Value of Surveillance FDG-PET/CT for Diffuse Large Cell B Cell Lymphoma in the Rituximab Era

Tailored Therapy In Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT, Can Lead to Modification and Safe Reduction In Therapy: Results of 134 Patients on the Israel National Hodgkin Study.

Not All Positive Interim PET/CT Scans Are Reliably Predictive for Progression Free Survival in Hodgkin Lymphoma (HL) Patients. A Proposed Model for a Functional Scoring Scale.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only